

---

## WilmerHale Represents Curis in \$45M Debt Transaction with HealthCare Royalty Partners

MARCH 30, 2017

Curis, Inc., a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, announced a \$45 million debt transaction with HealthCare Royalty Partners. The deal is meant to help fund an oncology pipeline for Curis.

The WilmerHale deal team that represented Curis included [John Sigel](#) and [Eric French](#).

For more information read Curis' [Fourth Quarter and Year-End Financial Results press release](#).